D-0235-2015 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0235-2015 was initiated by Pfizer Inc. on Oct 10, 2014 and is designated Class III. Reason for recall: Crystallization: Impurities in a raw material used to manufacture the diluent can cause the formation of crystals in the diluent vials after cold storage. The TORISEL vials are not affected by this… The recall status is terminated (terminated Apr 14, 2017). Affected quantity: 16,000 kits.

Recall details

Product Type
Drugs
Report Date
Nov 12, 2014
Initiation Date
Oct 10, 2014
Termination Date
Apr 14, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16,000 kits

Product description

TORISEL Kit (temsirolimus) injection, 25 mg/mL, 1 vial of TORISEL 25 mg/mL and 1 vial of 2.2 mL DILUENT per carton, Rx only, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA 19101; Diluent  MADE IN ITALY; NDC 0008-1179-01.

Reason for recall

Crystallization: Impurities in a raw material used to manufacture the diluent can cause the formation of crystals in the diluent vials after cold storage. The TORISEL vials are not affected by this issue.

Distribution pattern

Nationwide and Puerto Rico

Code information

Kit Lot #: AIEM/13, Exp 05/16 that contain diluent lots AHZW/11 and AHZW/12

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0235-2015
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0235-2015. Report a data issue: hello@regdatalab.com.